NEW YORK (GenomeWeb) – Paradigm today announced a partnership to provide its PCDx next-generation sequencing-based cancer diagnostic test to Translational Drug Development's (TD2) affiliated oncology provider networks.

The deal will provide oncologists in TD2's networks access to Paradigm's test in order to make tailored treatment decisions for patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.